Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet’s Keros Therapeutics KROS Stock Holding History

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-95,644	Closed	-$5.16M	–	98
2022 Q1	$5.16M	Hold	95,644	–	–	0.36%	67
2021 Q4	$5.6M	Hold	95,644	–	–	0.37%	71
2021 Q3	$3.78M	Hold	95,644	–	–	0.27%	79
2021 Q2	$4.06M	Buy	+95,644	New	+$5.18M	0.3%	76

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet's KROS Position: Q2 2022 in Review

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet sold out of Keros Therapeutics (KROS) in Q2 2022, closing a stake of 95,644 shares — an estimated $5.16M sold.

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet first reported a position in KROS in Q2 2021 and held it in 4 quarters. The position peaked at $5.6M in Q4 2021. 104 funds tracked by Wall St. Rank hold KROS as of Q2 2022.

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet reported no remaining Keros Therapeutics position as of Q2 2022 after selling out during the quarter.
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet sold 95,644 Keros Therapeutics shares in Q2 2022, an estimated $5.16M.
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet first reported a position in Keros Therapeutics in Q2 2021 and held it in 4 quarters.
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet's Keros Therapeutics position peaked at $5.6M in Q4 2021.
104 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2022.

Based on Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet's 13F filing for Q2 2022, filed 1 Aug 2022.